Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 9,10-seco- cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2007-08-14
2007-08-14
Pak, John (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
9,10-seco- cyclopentanohydrophenanthrene ring system doai
C514S878000, C514S879000, C514S903000
Reexamination Certificate
active
10858091
ABSTRACT:
A method for the treatment and prophylaxis of conditions of aging in humans, such conditions of aging associated with a decreased presence of one or more cell-specific carbonic anhydrase enzymes. Such conditions include chronic neurodegenerative conditions including dementia such as Alzheimer's disease. The method comprises administering to the patient a pharmaceutically effective, non-toxic amount of a compound that increases the presence of one or more cell-specific carbonic anhydrase enzymes whose levels are reduced in the patient. Such compound may be the cell-specific carbonic anhydrase enzyme, a compound that when absorbed by the body reacts or dissociates to form the cell-specific carbonic anhydrase enzyme, or a compound that promotes the natural generation of the cell-specific carbonic anhydrase enzyme within the body.
REFERENCES:
patent: 5929028 (1999-07-01), Skrabanja et al.
patent: 5939407 (1999-08-01), Landfield
patent: 6051566 (2000-04-01), Bianco
patent: 6552053 (2003-04-01), Sun et al.
patent: 6933278 (2005-08-01), Vickers et al.
patent: 6979468 (2005-12-01), Pollard
patent: 7045513 (2006-05-01), Parasrampuria et al.
Medline abstract, accession No. 2004372399 (2004).
Medline abstract, accession No. 2002203050 (May 2002).
Medline abstract, accession No. 97434650 (1997).
Medline abstract, accession No. 92304336 (1992).
Medline abstract, accession No. 2002058763 (Feb. 2002).
Medline abstract, accession No. 2001264687 (2001).
Medline abstract, accession No. 2001391287 (2001).
“Estrogen Study on Menopausal Women Is Stopped” by Brown,Washington Post, Wednesday, Mar. 3, 2004.
Abstract—“Progestins initiative adverse events of menopausal estrogen therapy” by Thomas, et al.,Climacteric(2003), 6(4), 293-301.
Abstract—“Effects of rofecoxib or naproxen vs. placebo on Alzheimer disease progression” by Aisen, et al.,JAMA, The Journal of the Amercian Medical Association(2003), 289(21), 2819-2826.
Abstract—“Current status of metals as therapeutic targets in Alzheimer's disease” by Finefrock, et al.,Journal of the American Geriatrics Society, (Aug. 2003) 51 (8) 1143-8.
Abstract—“Cysteamine-induced depletion of somatostatin produces differential cognitive deficits in rats” by DeNoble, et al.,Brain Research(1989), 482(1), 42-8.
Abstract—“Defective phorbol ester-stimulated secretion of .beta.-amyloid precursor protein from Alzheimer's disease fibroblasts” by Bergamaschi, et al.,Neuroscient Letters, (1995), 201(1), 1-4.
Abstract—“Age-dependent enzymatic changes in human cerebral cortex” by Reichlmeier, K.,Aktuelle Gerontol, Aug. 1978, 8(8):441-8.
Abstract—“Neurochemical findings in the aging brain” by Meier-Ruge, et al.,Adv. Biochem Psychopharmacol, 1980; 23:323-38.
Abstract—“Carbonic anydrase III. Oxidative modification in vivo and loss of phosphatase activity during Aging” by Cabiscol, et al.,J. Biol. Chem. Jun. 16, 1995;270(24):14742-7.
Abstract—“Addition of carbonic anhydrase augments extracellular pH buffering in rat cerebral cortex” by Huang, et al.,J. Neurophysiol, Oct. 1995;74(4):1806-9.
Abstract—“A comparative CD study of carbonic anhydrase isoenzymes with different number of tryptophans: impact on calculation of secondary structure content” by Boren, et al.,Protein Sci., Dec. 1996;5(12):2479-84.
Abstract—“Nonsteroidal anti-inflammatory drugs activate carbonic anhydrase by a direct mechanism of action” by Puscas, et al.,J. Pharmacol. Exp Ther, Jun. 1996;277(3):1464-6.
Abstract—“Efficacy of exogenous oral zinc in treatment of patients with carbonic anhydrase VI deficiency” by Henkin, et al.,Am J Med SciDec. 1999;318(6):392-405.
Abstract—“Intracellular zinc depletion induces caspase activation and p21 Waf1/Dip1 cleavage in human epithelial cell lines” Chai, et al.,J Ifect DisSep. 2000;182 Suppl 1:S85-92.
LandOfFree
Treatment of aging disorders in humans does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of aging disorders in humans, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of aging disorders in humans will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3851731